Predicting Methylphenidate Response in ADHD Using Machine Learning Approaches

Jae-Won Kim, Vinod Sharma, Neal D Ryan, Jae-Won Kim, Vinod Sharma, Neal D Ryan

Abstract

Background: There are no objective, biological markers that can robustly predict methylphenidate response in attention deficit hyperactivity disorder. This study aimed to examine whether applying machine learning approaches to pretreatment demographic, clinical questionnaire, environmental, neuropsychological, neuroimaging, and genetic information can predict therapeutic response following methylphenidate administration.

Methods: The present study included 83 attention deficit hyperactivity disorder youth. At baseline, parents completed the ADHD Rating Scale-IV and Disruptive Behavior Disorder rating scale, and participants undertook the continuous performance test, Stroop color word test, and resting-state functional MRI scans. The dopamine transporter gene, dopamine D4 receptor gene, alpha-2A adrenergic receptor gene (ADRA2A) and norepinephrine transporter gene polymorphisms, and blood lead and urine cotinine levels were also measured. The participants were enrolled in an 8-week, open-label trial of methylphenidate. Four different machine learning algorithms were used for data analysis.

Results: Support vector machine classification accuracy was 84.6% (area under receiver operating characteristic curve 0.84) for predicting methylphenidate response. The age, weight, ADRA2A MspI and DraI polymorphisms, lead level, Stroop color word test performance, and oppositional symptoms of Disruptive Behavior Disorder rating scale were identified as the most differentiating subset of features.

Conclusions: Our results provide preliminary support to the translational development of support vector machine as an informative method that can assist in predicting treatment response in attention deficit hyperactivity disorder, though further work is required to provide enhanced levels of classification performance.

Trial registration: ClinicalTrials.gov NCT01912352.

Keywords: ADHD; machine learning; methylphenidate; prediction; treatment response.

© The Author 2015. Published by Oxford University Press on behalf of CINP.

Figures

Figure 1.
Figure 1.
A research hypothesis for attention deficit hyperactivity disorder (ADHD). CPT, continuous performance test; DA, dopamine; MPH, methylphenidate; NE, norepinephrine; SCWT, Stroop color word test.
Figure 2.
Figure 2.
Comparison of area under the curve (AUC) performance of the classifiers on methylphenidate response. ROC, area under receiver operating characteristic (ROC) curve.

References

    1. Arnsten AF. (2011) Catecholamine influences on dorsolateral prefrontal cortical networks. Biol Psychiatry 69:e89–99.
    1. Biederman J, Faraone SV. (2005) Attention-deficit hyperactivity disorder. Lancet 366:237–248.
    1. Bohland JW, Saperstein S, Pereira F, Rapin J, Grady L. (2012) Network, anatomical, and non-imaging measures for the prediction of ADHD diagnosis in individual subjects. Front Syst Neurosci 6:78.
    1. Cho SC, Kim BN, Hong YC, Shin MS, Yoo HJ, Kim JW, Bhang SY, Cho IH, Kim HW. (2010) Effect of environmental exposure to lead and tobacco smoke on inattentive and hyperactive symptoms and neurocognitive performance in children. J Child Psychol Psychiatry 51:1050–1057.
    1. Cho SC, Hong YC, Kim JW, Park S, Park MH, Hur J, Park EJ, Hong SB, Lee JH, Shin MS, Kim BN, Yoo HJ, Cho IH, Bhang SY, Hahn S. (2013) Association between urine cotinine levels, continuous performance test variables, and attention deficit hyperactivity disorder and learning disability symptoms in school-aged children. Psychol Med 43:209–219.
    1. Cortese S. (2012) The neurobiology and genetics of Attention-Deficit/Hyperactivity Disorder (ADHD): what every clinician should know. Eur J Paediatr Neurol 16:422–433.
    1. Cox RW. (1996) AFNI: software for analysis and visualization of functional magnetic resonance neuroimages. Comput Biomed Res 29:162–173.
    1. Dosenbach NU, Nardos B, Cohen AL, Fair DA, Power JD, Church JA, Nelson SM, Wig GS, Vogel AC, Lessov-Schlaggar CN, Barnes KA, Dubis JW, Feczko E, Coalson RS, Pruett JR, Jr, Barch DM, Petersen SE, Schlaggar BL. (2010) Prediction of individual brain maturity using fMRI. Science 329:1358–1361.
    1. DuPaul GJ, Power TJ, Anastopoulos AD, Reid R. (1998) The ADHD Rating Scale-IV: checklists, norms, and clinical interpretation. New York: Guildford Press.
    1. Eubig PA, Aguiar A, Schantz SL. (2010) Lead and PCBs as risk factors for attention deficit/hyperactivity disorder. Environ Health Perspect 118:1654–1667.
    1. Fissell K, Tseytlin E, Cunningham D, Iyer K, Carter CS, Schneider W, Cohen JD. (2003) Fiswidgets: a graphical computing environment for neuroimaging analysis. Neuroinformatics 1:111–125.
    1. Froehlich TE, McGough JJ, Stein MA. (2010) Progress and promise of attention-deficit hyperactivity disorder pharmacogenetics. CNS Drugs 24:99–117.
    1. Golden CJ. (1978) The Stroop Color and Word Test. Chicago: Stoelting Company.
    1. Greenberg LM, Waldman ID. (1993) Developmental normative data on the test of variables of attention (T.O.V.A.). J Child Psychol Psychiatry 34:1019–1030.
    1. Greicius M. (2008) Resting-state functional connectivity in neuropsychiatric disorders. Curr Opin Neurol 21:424–430.
    1. Guy W. (1976) ECDEU Assessment manual for psychopharmacology, Revised. Rockville, MD: US Department of Health, Education, and Welfare.
    1. Hall M, Frank E, Holmes G, Pfahringer B, Reutemann P, Witten IH. (2009) The WEKA data mining software: an update. SIGKDD Explorations 11:10–18.
    1. Hawkins DM, Basak SC, Mills D. (2003) Assessing model fit by cross-validation. J Chem Inf Comput Sci 43:579–586.
    1. Herrmann MJ, Biehl SC, Jacob C, Deckert J. (2010) Neurobiological and psychophysiological correlates of emotional dysregulation in ADHD patients. Atten Defic Hyperact Disord 2:233–239.
    1. Hong SB, Kim JW, Cho SC, Shin MS, Kim BN, Yoo HJ. (2012) Dopaminergic and noradrenergic gene polymorphisms and response to methylphenidate in Korean children with attention-deficit/hyperactivity disorder: is there an interaction? J Child Adolesc Psychopharmacol 22:343–352.
    1. Hong SB, Harrison BJ, Fornito A, Sohn CH, Song IC, Kim JW. (2015) Functional dysconnectivity of corticostriatal circuitry and differential response to methylphenidate in youth with attention-deficit/hyperactivity disorder. J Psychiatry Neurosci 40:46–57.
    1. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, Williamson D, Ryan N. (1997) Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 36:980–988.
    1. Kebir O, Tabbane K, Sengupta S, Joober R. (2009) Candidate genes and neuropsychological phenotypes in children with ADHD: review of association studies. J Psychiatry Neurosci 34:88–101.
    1. Keerthi SS, Shevade SK, Bhattacharyya C, Murthy KRK. (2001) Improvements to Platt’s SMO algorithm for SVM classifier design. Neural Comput 13:637–649.
    1. Kim BN, Kim JW, Cummins TD, Bellgrove MA, Hawi Z, Hong SB, Yang YH, Kim HJ, Shin MS, Cho SC, Kim JH, Son JW, Shin YM, Chung US, Han DH. (2013) Norepinephrine genes predict response time variability and methylphenidate-induced changes in neuropsychological function in attention deficit hyperactivity disorder. J Clin Psychopharmacol 33:356–362.
    1. Kim Y, Cho SC, Kim BN, Hong YC, Shin MS, Yoo HJ, Kim JW, Bhang SY. (2010) Association between blood lead levels (<5 mug/dL) and inattention-hyperactivity and neurocognitive profiles in school-aged Korean children. Sci Total Environ 408:5737–5743.
    1. King JA, Tenney J, Rossi V, Colamussi L, Burdick S. (2003) Neural substrates underlying impulsivity. Ann N Y Acad Sci 1008:160–169.
    1. Kohavi R, John GH. (1997) Wrappers for feature subset selection. Artif Intell 97:273–324.
    1. Liston C, Malter Cohen M, Teslovich T, Levenson D, Casey BJ. (2011) Atypical prefrontal connectivity in attention-deficit/hyperactivity disorder: pathway to disease or pathological end point? Biol Psychiatry 69:1168–1177.
    1. Mick E, Faraone SV. (2008) Genetics of attention deficit hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 17:261–284, vii–viii.
    1. Nigg J, Nikolas M, Burt SA. (2010) Measured gene-by-environment interaction in relation to attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 49:863–873.
    1. Nigg JT, Knottnerus GM, Martel MM, Nikolas M, Cavanagh K, Karmaus W, Rappley MD. (2008) Low blood lead levels associated with clinically diagnosed attention-deficit/hyperactivity disorder and mediated by weak cognitive control. Biol Psychiatry 63:325–331.
    1. Orru G, Pettersson-Yeo W, Marquand AF, Sartori G, Mechelli A. (2012) Using Support Vector Machine to identify imaging biomarkers of neurological and psychiatric disease: a critical review. Neurosci Biobehav Rev 36:1140–1152.
    1. Power JD, Barnes KA, Snyder AZ, Schlaggar BL, Petersen SE. (2012) Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion. Neuroimage 59:2142–2154.
    1. Santosh PJ, Taylor E. (2000) Stimulant drugs. Eur Child Adolesc Psychiatry 9:I27–43.
    1. Siegle GJ, Thompson W, Carter CS, Steinhauer SR, Thase ME. (2007) Increased amygdala and decreased dorsolateral prefrontal BOLD responses in unipolar depression: related and independent features. Biol Psychiatry 61:198–209.
    1. Silva RR, Alpert M, Pouget E, Silva V, Trosper S, Reyes K, Dummit S. (2005) A rating scale for disruptive behavior disorders, based on the DSM-IV item pool. Psychiatr Q 76:327–339.
    1. Van Dijk KR, Sabuncu MR, Buckner RL. (2012) The influence of head motion on intrinsic functional connectivity MRI. Neuroimage 59:431–438.
    1. Wilens TE. (2008) Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 28:S46–53.
    1. Woods RP, Mazziotta JC, Cherry SR. (1993) MRI-PET registration with automated algorithm. J Comput Assist Tomogr 17:536–546.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다